Linked Life Data

19201387

Source:http://linkedlifedata.com/resource/pubmed/id/19201387

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2009-3-9
pubmed:abstractText
Peptide-based vaccines, one of several anti-tumor immunization strategies currently under investigation, can elicit both MHC Class I-restricted (CD8(+)) and Class II-restricted (CD4(+)) responses. However, the need to identify specific T-cell epitopes in the context of MHC alleles has hampered the application of this approach. We have tested overlapping synthetic peptides (OSP) representing a tumor antigen as a novel approach that bypasses the need for epitope mapping, since OSP contain all possible epitopes for both CD8(+) and CD4(+) T cells. Here we report that vaccination of inbred and outbred mice with OSP representing tumor protein D52 (TPD52-OSP), a potential tumor antigen target for immunotherapy against breast, prostate, and ovarian cancer, was safe and induced specific CD8(+) and CD4(+) T-cell responses, as demonstrated by development of specific cytotoxic T cell (CTL) activity, proliferative responses, interferon (IFN)-gamma production and CD107a/b expression in all mice tested. In addition, TPD52-OSP-vaccinated BALB/c mice were challenged with TS/A breast carcinoma cells expressing endogenous TPD52; significant survival benefits were noted in vaccine recipients compared to unvaccinated controls (p<0.001). Our proof-of-concept data demonstrate the safety and efficacy of peptide library-based cancer vaccines that obviates the need to identify epitopes or MHC backgrounds of the vaccinees. We show that an OSP vaccination approach can assist in the disruption of self-tolerance and conclude that our approach may hold promise for immunoprevention of early-stage cancers in a general population.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0264-410X
pubmed:author
pubmed:issnType
Print
pubmed:day
13
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1825-33
pubmed:meshHeading
pubmed-meshheading:19201387-Animals, pubmed-meshheading:19201387-Antigens, CD8, pubmed-meshheading:19201387-Breast Neoplasms, pubmed-meshheading:19201387-CD4-Positive T-Lymphocytes, pubmed-meshheading:19201387-CD8-Positive T-Lymphocytes, pubmed-meshheading:19201387-Cancer Vaccines, pubmed-meshheading:19201387-Cell Line, Tumor, pubmed-meshheading:19201387-Cell Proliferation, pubmed-meshheading:19201387-Epitopes, pubmed-meshheading:19201387-Immunohistochemistry, pubmed-meshheading:19201387-Interferon-gamma, pubmed-meshheading:19201387-Lysosomal-Associated Membrane Protein 2, pubmed-meshheading:19201387-Lysosome-Associated Membrane Glycoproteins, pubmed-meshheading:19201387-Mice, pubmed-meshheading:19201387-Mice, Inbred BALB C, pubmed-meshheading:19201387-Neoplasm Proteins, pubmed-meshheading:19201387-Recombinant Proteins, pubmed-meshheading:19201387-Survival, pubmed-meshheading:19201387-T-Lymphocytes, pubmed-meshheading:19201387-Vaccines, Subunit
pubmed:year
2009
pubmed:articleTitle
Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival.
pubmed:affiliation
Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, United States.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural